A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus

Journal of Virology

Volumn 86, Issue 7, 2012, Pages 3501-3512

  Lin, Tsai Yu ^a   Dowd, Kimberly A ^a   Manhart, Carolyn J ^a   Nelson, Steevenson ^a   Whitehead, Stephen S ^a   Pierson, Theodore C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; GREEN FLUORESCENT PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; EVOLUTION; GENETIC TRANSFECTION; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRUCTURAL GENE; VIRION; VIRUS GENOME; VIRUS NEUTRALIZATION; VIRUS RELEASE; WEST NILE FLAVIVIRUS;

ANIMALS; CELL LINE; DIRECTED MOLECULAR EVOLUTION; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTAGENESIS, SITE-DIRECTED; VIRAL ENVELOPE PROTEINS; WEST NILE FEVER; WEST NILE VIRUS;

MAMMALIA; WEST NILE VIRUS;

EID: 84861326671     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06435-11     Document Type: Article

References (80)

1. Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC. 2008. Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology 381: 67-74.
2. Asnis DS, Conetta R, Teixeira AA, Waldman G, Sampson BA. 2000. The West Nile virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin. Infect. Dis. 30: 413- 418.
3. Beasley DW, Barrett AD. 2002. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76: 13097-13100.
4. Beasley DW, et al. 2005. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J. Virol. 79: 8339-8347.
5. Beltramello M, et al. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271-283.
6. Calvert AE, et al. 2011. Human monoclonal antibodies to West Nile virus identify epitopes on the prM protein. Virology 410: 30 -37.
7. Castro C, Arnold JJ, Cameron CE. 2005. Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res. 107: 141-149.
8. Cherrier MV, et al. 2009. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 28: 3269- 3276.
9. Crill WD, Trainor NB, Chang GJ. 2007. A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J. Gen. Virol. 88: 1169 -1174.
10. Davis CW, et al. 2006. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol. 80: 1290- 1301.
11. Dejnirattisai W, et al. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745-748.
12. Donnelly ML, et al. 2001. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J. Gen. Virol. 82: 1013- 1025.
13. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7: e1002111.
14. Dowd KA, Pierson TC. 2011. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411: 306 -315.
15. Elshuber S, Allison SL, Heinz FX, Mandl CW. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 84: 183-191.
16. Falgout B, Chanock R, Lai CJ. 1989. Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a. J. Virol. 63: 1852-1860.
17. Geiss BJ, Pierson TC, Diamond MS. 2005. Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA. Virol. J. 2: 53.
18. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 349- 360.
19. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82: 8828-8837.
20. Guirakhoo F, Bolin RA, Roehrig JT. 1992. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology 191: 921-931.
21. Guirakhoo F, Heinz FX, Mandl CW, Holzmann H, Kunz C. 1991. Fusion activity of flaviviruses: comparison of mature and immature (prMcontaining) tick-borne encephalitis virions. J. Gen. Virol. 72(Pt 6): 1323- 1329.
22. Harrison SC. 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15: 690-698.
23. Heinz FX, et al. 1994. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198: 109 -117.
24. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59.
25. Hubalek Z, Halouzka J. 1999. West Nile fever-a reemerging mosquitoborne viral disease in Europe. Emerg. Infect. Dis. 5: 643- 650.
26. Jin Z, Deval J, Johnson KA, Swinney DC. 2011. Characterization of the elongation complex of dengue virus RNA polymerase: assembly, kinetics of nucleotide incorporation, and fidelity. J. Biol. Chem. 286: 2067-2077.
27. Junjhon J, et al. 2010. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 84: 8353- 8358.
28. Kaufmann B, et al. 2006. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 103: 12400 -12404.
29. Kaufmann B, et al. 2010. Neutralization of West Nile virus by crosslinking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. U. S. A. 107: 18950 -18955.
30. Khromykh AA, Meka H, Guyatt KJ, Westaway EG. 2001. Essential role of cyclization sequences in flavivirus RNA replication. J. Virol. 75: 6719- 6728.
31. Khromykh AA, Sedlak PL, Westaway EG. 2000. cis- and trans-acting elements in flavivirus RNA replication. J. Virol. 74: 3253-3263.
32. Khromykh AA, Varnavski AN, Sedlak PL, Westaway EG. 2001. Coupling between replication and packaging of flavivirus RNA: evidence derived from the use of DNA-based full-length cDNA clones of Kunjin virus. J. Virol. 75: 4633- 4640.
33. Khromykh AA, Varnavski AN, Westaway EG. 1998. Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans. J. Virol. 72: 5967-5977.
34. Kim JM, et al. 2008. A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. J. Virol. 82: 7846-7862.
35. Kuhn RJ, et al. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717-725.
36. Lauring AS, Andino R. 2010. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 6: e1001005.
37. Li L, Barrett AD, Beasley DW. 2005. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology 335: 99 -105.
38. Li L, et al. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319: 1830 -1834.
39. Lindenbach BD, Thiel HJ, Rice CM. 2007. Flaviviridae: the viruses and their replication, p 1101-1152. In Knipe DM, et al. (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
40. Lok SM, et al. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15: 312-317.
41. Mackenzie JS, Gubler DJ, Petersen LR. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10: S98 -S109.
42. Matsui K, et al. 2009. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384: 16 -20.
43. McGee CE, et al. 2009. Infection, dissemination, and transmission of a West Nile virus green fluorescent protein infectious clone by Culex pipiens quinquefasciatus mosquitoes. Vector Borne Zoonotic Dis. 10: 267- 274.
44. Mehlhop E, et al. 2009. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6: 381-391.
45. Montgomery SP, et al. 2005. Rhabdomyolysis in patients with West Nile encephalitis and meningitis. Vector Borne Zoonotic Dis. 5: 252-257.
46. Mukhopadhyay S, Kuhn RJ, Rossmann MG. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3: 13-22.
47. Nelson S, et al. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4: e1000060.
48. Nelson S, Poddar S, Lin TY, Pierson TC. 2009. Protonation of individual histidine residues is not required for the pH-dependent entry of West Nile virus: evaluation of the "histidine switch"hypothesis. J. Virol. 83: 12631- 12635.
49. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. 2006. Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 80: 11467-11474.
50. Nybakken GE, et al. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437: 764 -769.
51. Oliphant T, et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11: 522-530.
52. Oliphant T, et al. 2007. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81: 11828 -11839.
53. Oliphant T, et al. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 80: 12149 -12159.
54. Pierson TC, et al. 2005. An infectious West Nile virus that expresses a GFP reporter gene. Virology 334: 28-40.
55. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229 -238.
56. Pierson TC, et al. 2006. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346: 53- 65.
57. Pierson TC, et al. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135-145.
58. Rice CM, Grakoui A, Galler R, Chambers TJ. 1989. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1: 285-296.
59. Rodenhuis-Zybert IA, et al. 2010. Immature dengue virus: a veiled pathogen? PLoS Pathog. 6: e1000718.
60. Roehrig JT. 2003. Antigenic structure of flavivirus proteins. Adv. Virus Res. 59: 141-175.
61. Rossi SL, Ross TM, Evans JD. 2010. West Nile virus. Clin. Lab. Med. 30: 47- 65.
62. Roth DB, Wilson JH. 1985. Relative rates of homologous and nonhomologous recombination in transfected DNA. Proc. Natl. Acad. Sci. U. S. A. 82: 3355-3359.
63. Ruggli N, Rice CM. 1999. Functional cDNA clones of the Flaviviridae: strategies and applications. Adv. Virus Res. 53: 183-207.
64. Sejvar JJ. 2007. The long-term outcomes of human West Nile virus infection. Clin. Infect. Dis. 44: 1617-1624.
65. Shi PY, Tilgner M, Lo MK, Kent KA, Bernard KA. 2002. Infectious cDNA clone of the epidemic West Nile virus from New York City. J. Virol. 76: 5847-5856.
66. Shustov AV, Mason PW, Frolov I. 2007. Production of pseudoinfectious yellow fever virus with a two-component genome. J. Virol. 81: 11737- 11748.
67. Stadler K, Allison SL, Schalich J, Heinz FX. 1997. Proteolytic activation of tick-borne encephalitis virus by furin. J. Virol. 71: 8475- 8481.
68. Stiasny K, Brandler S, Kossl C, Heinz FX. 2007. Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J. Virol. 81: 11526 -11531.
69. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80: 9557-9568.
70. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. 1998. West Nile encephalitis epidemic in southeastern Romania. Lancet 352: 767-771.
71. Vazquez S, et al. 2002. Immune response to synthetic peptides of dengue prM protein. Vaccine 20: 1823-1830.
72. Villordo SM, Gamarnik AV. 2009. Genome cyclization as strategy for flavivirus RNA replication. Virus Res. 139: 230 -239.
73. Wong SH, Smith DW, Fallon MJ, Kermode AG. 2005. Murray valley encephalitis mimicking herpes simplex encephalitis. J. Clin. Neurosci. 12: 822-824.
74. Yamshchikov VF, Wengler G, Perelygin AA, Brinton MA, Compans RW. 2001. An infectious clone of the West Nile flavivirus. Virology 281: 294-304.
75. Yewdell JW, Webster RG, Gerhard WU. 1979. Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature 279: 246 -248.
76. Yu IM, et al. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319: 1834 -1837.
77. Zhang S, et al. 2010. Role of BC loop residues in structure, function and antigenicity of the West Nile virus envelope protein receptor-binding domain III. Virology 403: 85-91.
78. Zhang S, et al. 2009. Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. J. Infect. Dis. 200: 202-205.
79. Zhang Y, et al. 2003. Structures of immature flavivirus particles. EMBO J. 22: 2604 -2613.
80. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG. 2007. Structure of immature West Nile virus. J. Virol. 81: 6141- 6145.